Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree

BACKGROUND: The hepatitis C virus (HCV) prevalence rate among injection drug users (IDUs) in North America is 55.2%, with 1.41 million individuals estimated to be HCV-antibody positive. Studies have shown the effectiveness of syringe service programs (SSPs) alone, medications for opioid use disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Ijioma, Stephen C, Pontinha, Vasco M, Holdford, David A, Carroll, Norman V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391166/
https://www.ncbi.nlm.nih.gov/pubmed/33506729
http://dx.doi.org/10.18553/jmcp.2021.27.2.137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391166/
https://www.ncbi.nlm.nih.gov/pubmed/33506729
http://dx.doi.org/10.18553/jmcp.2021.27.2.137

Ejemplares similares